Home > Boards > US Listed > Biotechs > Halozyme Therapeutics (HALO)

HALO's weird new job posting:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Fred Kadiddlehopper Member Profile
 
Followed By 24
Posts 3,405
Boards Moderated 1
Alias Born 09/22/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 8:20:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 1:41:16 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/7/2019 5:11:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:45:58 PM
Halozyme To Participate In Upcoming Investor Conferences PR Newswire (US) - 6/4/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 5:24:28 PM
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement PR Newswire (US) - 5/22/2019 1:05:00 AM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:11:52 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:08:35 PM
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire (US) - 5/13/2019 8:01:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2019 4:14:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 4:07:11 PM
Halozyme Reports First Quarter 2019 Results PR Newswire (US) - 5/7/2019 4:01:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/6/2019 4:02:13 PM
Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development PR Newswire (US) - 5/6/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/3/2019 5:08:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:30:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:26:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:23:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:21:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:18:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:14:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:11:43 PM
Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call PR Newswire (US) - 4/23/2019 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/15/2019 4:09:46 PM
Fred Kadiddlehopper   Thursday, 02/14/19 09:32:23 AM
Re: None
Post # of 5631 
HALO's weird new job posting:

-------------------------------

Vice President, Corporate Development

POSITION SUMMARY:

The Vice President, Oncology Business Development will report to the CEO and, in partnership with the Executive Team, will define and execute Halozyme’s plan to build a multi-product oncology company. S/he will drive the company’s growth strategy through the identification, evaluation, execution, and integration of compelling acquisition and investment opportunities complementary to our two pillar business.

ESSENTIAL FUNCTIONS AND RESPONSIBILITIES:

These may include but are not limited to:

Develop a vision for a Halozyme oncology portfolio that will excite and engage investors
Lead execution of diligence, detailed assessment and valuation of oncology companies and assets identified as potentially attractive for Halozyme to access
Lead and execute the end-to-end M&A process, including identification of key value drivers during diligence, creation, and execution of the integration plan and monitoring and reporting of and business objectives
Recommend approach and terms for acquisition/licensing of new assets
Lead process for evaluation, selection and negotiation with regional partners
Develop valuation model for potential regional partnerships opportunities
Establish internal process for rapid search and evaluation for identification of new asset opportunities and newly emerging competitive threats and as we build our portfolio
Cultivate robust network with banks, companies, and opinion leaders to facilitate deal identification and consummation
Manage reporting of asset’s long-term value, operational achievements, risks, and dependencies; proactively identify potential planning gaps, suggest mitigation's to open issues/risks and drive resolutions
Create integration processes/playbooks that incorporate prior experience and industry best practices across the cross-functional team

ADDITIONAL FUNCTIONS AND RESPONSIBILITIES:

Identify new ENHANZE opportunities and new platform technologies and communicate these to ENHANZE Business Development team
Other duties as assigned

EDUCATION, EXPERIENCE, KNOWLEDGE, SKILLS AND ABILITIES:

A minimum of a Bachelor’s degree with at least 15 years’ business development experience within the biopharmaceutical industry (and equivalent combination of education and experience may be considered)
Demonstrated track record of success leading a range of transactions including company or asset acquisition, out-licensing assets and mergers and acquisitions
Proven experience playing major role on transactions in pharma/biotech
Previous experience as an investor or working within Private Equity Group assessing and making recommendations on acquisitions of companies or assets
Former scientific and commercialization expertise in oncology
Expert level skills building deal models
Deep knowledge of US and EU markets; Asia Pac experience, a plus
MS, PhD, MD, CFA or MBA preferred

TECHNICAL KNOWLEDGE REQUIRED:

Equipment: PC, scanners, facsimile machine, voice mail and e-mail systems, and common office machines, or ability to be trained.

Software Knowledge : Windows, MS Office (Outlook, Word, Excel, PowerPoint, Visio)

INTERNAL AND EXTERNAL RELATIONSHIPS:

Develop internal and external relationships that successfully drive business objectives
Collaborate with cross-functional teams consisting of functional experts and target company leaders throughout the M&A process

EFFORT REQUIRED/ENVIRONMENTAL CONDITIONS:

Physical Activities : On a continuous basis, sit at desk for a long period of time; intermittently answer telephone and write or use a keyboard to communicate through written means. Some walking and lifting up to 20 lbs. may be required. The noise level in the work environment is usually low to moderate. The physical demands described above are representative of those that must be met by an employee to successfully perform the essential functions and responsibilities of this job. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions and responsibilities.

Laboratory Activities, if applicable: Biology and chemical laboratory environments experience needed. Environmental health and safety requirements also apply.

TRAVEL:

Travel may be required up to 50% of your time

The more you know, the less you don't know.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist